Genomic Study of Dipeptidyl Peptidase-4 (DPP-4) and Glucagon-Like Peptide 1 Receptor (GLP1R) in Chinese and it's Apply in Antidiabetes

2017-04-12 04:08:21 | BioPortfolio


With the development of pharmacogenomics and pharmacogenetics, personalized medicine based on genetic are increasingly required clinically. Incretin-based therapy is currently the most popular diabetes treatment. This study mainly research the correlation of incretin-related gene polymorphism and individual differences in the response of these drugs from the following four aspects.

1. . To study Chinese human gene polymorphism's mutation frequency and allele frequency, by screening Chinese people gene polymorphisms which affecting DPP-4 enzymatic activity.

2. . To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.

3. . By collecting clinical parameters and efficacy indicators to reveal the relationship between Chinese DPP-4 gene and GLP1R gene polymorphism on the clinical manifestations and drug response. This study will be improved based on actual experimental research methods, and design intervening measures for Chinese people, to explore the dose-effect relationship of DPP-4 and GLP1R gene polymorphism in the treatment of diabetes in Chinese population.

4. . Incretins is a new generation hypoglycemic agent. By studying gene polymorphism and drug response, to research how to plan treatment for clinical diabetes with DPP-4 and GLP1R gene polymorphism. Provide the basis for individualized treatment of these drugs.

Study Design


Diabetes Mellitus


Sitagliptin, Liraglutide


Sichuan provincial people's hospital




Sichuan Provincial People's Hospital

Results (where available)

View Results


Published on BioPortfolio: 2017-04-12T04:08:21-0400

Clinical Trials [3949 Associated Clinical Trials listed on BioPortfolio]

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin...

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects

A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus

A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic...

PubMed Articles [3756 Associated PubMed Articles listed on BioPortfolio]

Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.

Diabetes mellitus is a progressive disease with cardiovascular complications. This study evaluated the effects of liraglutide, a glucagon-like peptide-1 analog, and the dipeptidyl peptidase 4 inhibito...

Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD.

To investigate the effect of anti-diabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control...

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascula...

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and Cardiovascular Outcomes in Typ...

Metformin, Sitagliptin, and Liraglutide modulate serum retinol binding protein -4 level and adipocytokines production in type 2 diabetes mellitus rat model.

Many adipocytokines correlate with obesity and insulin resistance(IR). we examined the effects of metformin, sitagliptin, and liraglutide in diabetic rats. Group 1: control normal (CN) received oral s...

Medical and Biotech [MESH] Definitions

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

More From BioPortfolio on "Genomic Study of Dipeptidyl Peptidase-4 (DPP-4) and Glucagon-Like Peptide 1 Receptor (GLP1R) in Chinese and it's Apply in Antidiabetes"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Searches Linking to this Trial